Overview of Фталазол

Quick Facts

Property	Description
Active ingredient	Phthalylsulfathiazole (INN)
Form	Tablets (Oral administration)
Pharmacological class	Sulfonamide antimicrobial agent, Intestinal antiseptic
General purpose	Local control of susceptible bacteria in the gut
Origin	Synthetic derivative

What Type of Medicine is Фталазол?

Фталазол is a synthetic medicinal product classified as a sulfonamide antimicrobial agent and an intestinal antiseptic. Its active ingredient is Phthalylsulfathiazole (INN), which is administered via the oral route as a single-ingredient product in tablet form. Sulfonamides are a specific class of chemotherapeutic agents used to inhibit the growth of susceptible bacteria. The substance Phthalylsulfathiazole is chemically modified to ensure its primary action is restricted to the gastrointestinal tract, defining its specialized localized role. This approach of local delivery is clinically recognized for minimizing systemic exposure, which differentiates it from older, systemically absorbed sulfonamides.

Composition and Unique Intestinal Action

The compound Phthalylsulfathiazole is a synthetic derivative whose chemical design facilitates low systemic absorption from the gut. This means the majority of the substance remains highly concentrated in the intestinal lumen, maximizing its local effect while minimizing its distribution throughout the body. The compound achieves its bacteriostatic effect by interfering with the bacteria’s vital process of folic acid synthesis, which is essential for microbial reproduction. This minimal absorption profile is critical for its targeted application.

What is the General Purpose of this Intestinal Antiseptic?

The general purpose of Фталазол is to provide highly focused, non-systemic antimicrobial activity within the digestive tract. This localized action establishes the product as an intestinal antiseptic, helping to manage bacterial populations in the gut. By suppressing microbial multiplication via its bacteriostatic mechanism, Фталазол is typically used to help control discomfort and symptoms associated with bacterial overgrowth or related enteric pathology, such as when managing symptoms during a short period of gastrointestinal upset. This focused benefit is the distinguishing feature of the Phthalylsulfathiazole formulation.

What side effects are possible with Фталазол?

Possible Side Effects and Safety Information

The safety profile of Phthalylsulfathiazole ( Фталазол) is formally defined by adverse reactions categorized by their frequency and the system-organ classes affected, as documented in regulatory sources.

Since Фталазол is primarily designed for local action within the gastrointestinal tract, the most frequently classified effects are related to the digestive system, while less common and rare effects reflect the potential systemic risks of the sulfonamide class it belongs to.

Frequency Classification	System-Organ Classes Involved
Common	Gastrointestinal Disorders
Uncommon	Immune System Disorders, Skin and Subcutaneous Tissue Disorders
Rare	Blood and Lymphatic System Disorders, Renal and Urinary Disorders, Hepato-biliary Disorders

Common adverse reactions typically include nausea, vomiting, and anorexia (loss of appetite). Uncommon reactions include mild hypersensitivity manifestations, such as fever and skin rash.

Serious Adverse Reactions and Restrictions

Official labeling documents explicitly list rare but serious adverse reactions known to the sulfonamide class. These include severe hematological disorders, such as aplastic anemia and agranulocytosis, as well as life-threatening dermatological events, specifically Stevens-Johnson syndrome (SJS).

Safety notes also outline population-specific considerations and restrictions. The medication is contraindicated in cases of known hypersensitivity to any sulfonamide and in patients with severe hepatic or renal impairment. Caution is also specified for individuals with G6PD deficiency and is contraindicated in infants under two months and during the late stage of pregnancy.

Overdose and Emergency Response

Overdose and When to Seek Help

The overdose profile for Phthalylsulfathiazole, as documented in official regulatory guidance, is structured around mandated emergency response actions and supportive care, rather than a specific list of clinical symptoms. Official regulatory documents currently do not specify a clinical symptom profile for human ingestion of the compound, nor do they detail specific severity classifications or dose-related factors associated with overdose.

When Urgent Medical Help Is Required

Regulatory authorities issue clear mandates for seeking professional help. It is required to seek medical advice immediately following a suspected overdose, an accidental ingestion, or if the individual feels unwell. Furthermore, medical attention must be obtained if symptoms occur or persist after the exposure event. These statements underscore the need for immediate professional assessment.

Management and Antidote

Official guidance specifies that treatment for overdose situations is focused on symptomatic and supportive management. A key procedural instruction states that one should DO NOT induce vomiting if the substance has been swallowed; the mouth should instead be thoroughly rinsed with water. Regulatory information confirms that no specific antidote is known for Phthalylsulfathiazole overdose. There are no explicit requirements for extended hospital monitoring or documented population-specific considerations (such as for the elderly or those with existing impairments) within the emergency sections of the official labeling.

Therapeutic Uses of Фталазол

What Фталазол Treats: Main Uses and Benefits

The utility of Фталазол (Phthalylsulfathiazole) is relevant in contexts marked by increased discomfort or tension, applied across therapeutic domains where additional symptomatic support is needed. The medication is commonly used to help with specific gastrointestinal infections, including acute bacterial enteric infections, infectious colitis, and bacterial dysentery.

It is used to address pronounced symptoms related to heightened physiological activity, such as high stool frequency, watery stools, and the painful straining sensation known as tenesmus. The primary therapeutic benefit is to offer supportive relief, which helps ease the overall symptom burden during these periods of heightened stress.

Beyond acute illness, Фталазол is considered relevant in specialized clinical scenarios, such as pre-operative bowel preparation in situations requiring temporary assistance in symptom stabilization, and applied in scenarios where additional management of colonization is appropriate after acute infection.

“The medication supports the patient during difficult episodes by easing distress and contributing to improved day-to-day comfort.”

Quick Fact: Relief for Acute Gut Discomfort

Symptom Cluster	Primary Benefit	Use Context
Acute Diarrheal Distress	Helps manage symptom clusters that may become disruptive.	Acute Travelers' Diarrhea or Food Poisoning.
Abdominal Cramping/Pain	Supports the relief of symptoms related to inflammatory or irritative states.	Conditions characterized by inflammatory states.

Eligibility and Restrictions for Use

The eligibility criteria for Фталазол (Phthalylsulfathiazole) are strictly defined by regulatory authorities to exclude specific population groups and pre-existing conditions.

Contraindicated Populations

Absolute contraindications include individuals with a known hypersensitivity or allergy to sulfonamide antibiotics. The medicine must not be used by patients with severe hepatic dysfunction (liver disease) or severe renal dysfunction (kidney disease). Use is also prohibited in patients with intestinal obstruction and certain severe blood disorders.

Age and Physiological Restrictions

Age-related eligibility excludes infants (especially neonates under two months) due to risks associated with the sulfonamide class, and use in young children is generally restricted or conditional. The product is strictly contraindicated during the third trimester of pregnancy. Furthermore, the use of Фталазол is generally not recommended while breastfeeding.

Conditions Requiring Conditional Use

Individuals with mild to moderate renal or hepatic impairment may be eligible, but use is conditional and requires close supervision. Restricted eligibility also applies to patients with G6PD deficiency or a history of acute porphyria.

What should I know about interactions with other medicines?

The official interaction profile for Phthalylsulfathiazole (Фталазол) is defined by its potential to modify the exposure and pharmacodynamic risks of co-administered systemic medications, alongside administration rules related to its localized intestinal action.

Interaction Category	Interacting Agents / Classes	Official Regulatory Outcome
Exposure Enhancement	Oral Anticoagulants (e.g., Warfarin); Antidiabetic Agents (e.g., Insulin, Sulfonylureas)	Potentiation of effects; Enhanced hypoglycemic effects.
Additive Risk	Nephrotoxic Agents (e.g., Cyclosporine); NSAIDs; Other Sulfonamides	Increased risk of specific adverse effects, including renal failure.
Absorption Interference	Oral Adsorbents (e.g., Cholestyramine, Colesevelam)	Reduced absorption of Phthalylsulfathiazole, which requires mandatory time separation during administration.

Official Interaction Statements:

Phthalylsulfathiazole is documented to potentiate the effect of oral anticoagulants.
The combination with antidiabetic agents enhances the risk of hypoglycemia.
Co-administration with specific NSAIDs or nephrotoxic agents may increase the risk of specific adverse effects.
Renal excretion competition has been observed with certain transporter substrates, such as Benzylpenicillin, potentially increasing its systemic concentration.

Connection to the overall interaction profile: Regulatory documents define the product’s interaction structure primarily through its ability to increase the effects of systemic drugs and contribute to additive toxicity. This profile also establishes a mandatory timing constraint with oral adsorbents to ensure the intended intestinal concentration is maintained.

Mechanism of Action

Prodrug Activation and Localized Intestinal Action

The mechanism relies on the administered compound, Phthalylsulfathiazole, functioning as a prodrug that is intentionally designed for poor systemic absorption. This structure ensures the drug is primarily active in the gut lumen, where it undergoes hydrolysis to release the biologically functional molecule, Sulfathiazole. This process restricts the drug's activity to the periphery, localizing the pharmacological effect to the gastrointestinal lumen.

Competitive Inhibition of Bacterial Metabolism

The core effect is established by Sulfathiazole acting as a competitive antagonist against the bacterial substrate PABA at the enzyme dihydropteroate synthetase (DHPS). By binding to DHPS, the drug blocks the synthesis of dihydrofolic acid, which starves the microbe of precursors (purines and pyrimidines) needed for DNA and RNA creation. This molecular cascade results in a bacteriostatic state, which halts the proliferation of susceptible bacteria.

Localized Modulation of Inflammatory Pathways

The drug exerts a secondary, localized influence on intestinal inflammatory pathways. This involves modulating the activity of the immune system by limiting the migration of leukocytes (immune cells) into the gut mucosa. This anti-inflammatory action dampens the intensity of the immune response, resulting in the reduction of localized inflammatory cellular exudate and edema.

Dosage and Administration Information

The administration of Фталазол (Phthalylsulfathiazole) is structured by a phased, short-term course of use. The approved route is oral administration via the tablet form, consistent with its design for highly localized activity within the intestinal tract.

Adult Dosing and Frequency

The standard regimen follows a step-down schedule typically spanning five to seven days. This structure mandates both a high frequency and a defined maximum dose in the initial phase. For instance, the course may begin with a total daily dose not exceeding 6 grams (e.g., 1 g administered every four hours), establishing the high concentration needed for its function. The administration frequency and maximum daily dose are gradually reduced in subsequent phases; by the end of the course, the daily maximum may fall to 3 grams (e.g., 1 g administered every eight hours). This systematic reduction is a component of the use protocol.

Specific Administration Conditions

The tablets should be taken with a sufficient volume of water. The use is restricted by the defined maximum dose allowed in each phase of the course. For pediatric patients, dosing is calculated based on the child’s body weight in kilograms. Separate weight-based dose ranges and frequency schedules are provided for children under three years old versus those above three years, ensuring the appropriate administration principle is applied to distinct age groups. The overall use is confined to this short-term, fixed duration.

Recent Clinical Evidence

Фталазол (Phthalylsulfathiazole): Overview of Clinical Research

Phthalylsulfathiazole, a sulfonamide antimicrobial, has historically been used for treating certain gastrointestinal (GI) infections. Its primary characteristic is its poor absorption into the bloodstream, allowing it to exert its main effect locally within the intestines. This localized action is the focus of much of the historical clinical evidence.

Studies have investigated the theoretical approach of the drug's potential target. It is considered a prodrug that undergoes hydrolysis in the intestinal tract to release the active compound, sulfathiazole. This active component is a structural analog of para-aminobenzoic acid (PABA) and is associated with inhibiting the bacterial synthesis of folic acid, an essential substance for bacterial growth and replication.

Efficacy and Target Organisms

Research has evaluated the drug's association with symptom changes in intestinal conditions. Clinical data supports its use in bacterial infections such as:

Dysentery
Colitis
Gastroenteritis

It is also noted that the drug has been evaluated for use as a preoperative preparation measure in intestinal surgery to reduce the bacterial load. The antimicrobial activity is directed against various Gram-positive and Gram-negative bacteria, including certain strains of Escherichia coli, Salmonella, and Shigella species.

Safety Profile and Co-Administration

Research has addressed the incidence of potential adverse events in trial participants, which commonly includes gastrointestinal discomfort like nausea and stomach upset. Due to its limited systemic absorption, the risk of some systemic side effects is reduced compared to other sulfonamides, though rare hematologic or severe allergic reactions are possible.

Co-administration research has explored potential interactions, such as those with certain oral anticoagulants or antidiabetic agents, where caution and monitoring are typically warranted. The efficacy of the drug may also be altered when taken alongside certain bile acid sequestrants.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Фталазол (FAQ)

Q: Does Фталазол work to stop all kinds of diarrhea?

A: According to official documents, Фталазол is indicated for diarrhea and intestinal infections caused by susceptible bacteria, such as Shigella and certain strains of E. coli. The drug works locally as an intestinal antiseptic, meaning its action is limited to bacterial sources and may not address diarrhea from other causes (e.g., viral or parasitic).

Q: How often do people experience allergic skin reactions while using Фталазол?

A: Official product information classifies mild allergic responses, including skin rash and fever, as uncommon side effects. This means they are not frequently reported, but are documented as potential effects of the medication.

Q: Are there risks associated with long-term or repeated use of Фталазол?

A: Regulatory guidelines outline the standard administration of Фталазол as a short-term, fixed-duration course. The official protocol for this drug does not include long-term or chronic use for its approved indications.

Q: Can Фталазол be taken with common pain relievers like paracetamol?

A: Regulatory warnings identify an additive risk when Фталазол is combined with certain pain relievers, specifically non-steroidal anti-inflammatory drugs (NSAIDs). The official interaction profile does not typically list specific contraindications for Paracetamol (Acetaminophen) itself.

Q: How quickly does Фталазол leave the body after the last dose?

A: The drug is intentionally designed for poor systemic absorption, ensuring that the majority of the active substance remains highly concentrated in the intestinal tract. Official pharmacokinetic information states that the drug is primarily eliminated from the body via the feces.

Q: Is there any research evidence confirming the use of Фталазол for traveler's diarrhea?

A: Studies and official indications support the use of Фталазол for gastroenteritis and bacterial infections caused by specific organisms like E. coli. While not always explicitly named, these indications cover many cases of traveler’s diarrhea.

Q: Does Фталазол affect the good bacteria in the gut?

A: Official guidance suggests that the drug's effect as an intestinal antiseptic may influence the bacterial populations in the gut. Due to a potential decrease in the natural synthesis of B vitamins, supplementary B vitamins may be considered during use.

Q: Can Фталазол be used to treat symptoms of general stomach upset or bloating?

A: The general purpose of this medicine is to treat and manage symptoms associated with susceptible bacterial infections within the gastrointestinal tract, such as colitis or dysentery. It is not officially indicated for the treatment of general, nonspecific stomach upset or bloating.

Q: Does the medicine need to be taken with food or on an empty stomach?

A: Official administration instructions stipulate that the tablets must be taken with a sufficient volume of water. However, regulatory documents typically do not specify whether the medication needs to be taken with food or on an empty stomach.

Q: Are there other medications with the same active substance as Фталазол?

A: Regulatory chemical summaries list the active substance as Phthalylsulfathiazole. Products containing this exact active ingredient may be marketed in different countries under various local trade names.

Q: Is Фталазол available in liquid or suspension form for children?

A: According to the official product information and pharmaceutical listings, Фталазол is available only in the form of tablets. No liquid or oral suspension forms are currently documented.

Q: Is it a common experience to feel tired or dizzy after taking Фталазол?

A: Official adverse reaction reports list dizziness and headache as potential neurological side effects, although they are generally classified as less common.

Q: Does Фталазол interact with oral contraceptives?

A: Official safety information includes a general warning that if the drug causes severe diarrhea or vomiting (which are potential side effects), the effectiveness of oral contraceptive pills may be reduced.

Q: Are there specific vitamins or supplements that should be avoided when using Фталазол?

A: Official guidance specifically suggests the supplementary intake of B vitamins during the course of treatment. The drug's mechanism does not typically require the avoidance of general vitamin supplements.

Q: Does Фталазол interact with alcohol consumption?

A: Regulatory documents do not typically list alcohol as a formal contraindication. However, combining alcohol with this medication may increase the risk of certain side effects like dizziness or gastrointestinal upset.

Q: Are there any specific food restrictions mentioned in the official labeling for Фталазол?

A: Official labeling is focused on specific drug-drug interactions and timing with oral adsorbents. Regulatory documents do not typically list any specific food restrictions for Фталазол.

Q: Are there specific considerations for using Фталазол in elderly patients?

A: Official adult dosing guidelines generally do not distinguish between the general adult population and elderly patients. However, the existing cautions regarding use in patients with severe kidney or liver impairment remain relevant, as these conditions are more common in older adults.

Q: Is there concern about bacterial resistance developing to Фталазол?

A: Regulatory guidance for antibacterial agents typically includes a general caution regarding the potential development of drug-resistant bacteria. This highlights the need for appropriate use.

Q: Is Фталазол a prescription-only medicine?

A: The regulatory classification of the medicine varies by market and pack size. In some markets, small packages of the 500 mg tablets may be classified as Non-Prescription (OTC), while larger quantities may require a prescription.

Q: Is it true that Фталазол can cause constipation?

A: Official documentation of gastrointestinal side effects focuses on symptoms like nausea, vomiting, and loss of appetite. Constipation is not typically listed as a common or uncommon adverse reaction to the medication.

Q: Is Фталазол considered a medication that is photosensitive (reacts to sun exposure)?

A: Due to the drug's classification as a sulfonamide, safety warnings often reference the need to avoid excessive sun exposure during the period of use to mitigate the potential risk of photosensitivity.

Q: Does Фталазол come in different strengths?

A: Official regulatory documents and pharmaceutical forms consistently describe the marketed tablet as containing a single strength of 500 mg of the active substance.

Q: Is the medication considered safe for individuals with lactose intolerance?

A: Official documentation lists Lactose monohydrate as one of the inactive ingredients (excipients). This is a factor for individuals who have known lactose intolerance.

Q: What happens if a dose is accidentally missed?

A: Regulatory documents describe the procedure when a dose is forgotten as taking it as soon as remembered, unless it is nearly time for the next scheduled dose.

Q: Is Фталазол commonly used in veterinary medicine?

A: FDA records indicate that the related active compound, Sulfathiazole (the drug's active metabolite), is designated as a bulk ingredient that can be used for animal drug compounding.

Q: Are there any known issues with driving or operating machinery while taking Фталазол?

A: Official documents often state that the drug may have no or negligible influence on the ability to drive or operate machinery. The official label may advise caution due to the potential for side effects like dizziness.

How should Фталазол be stored and disposed of?

How to Store and Dispose of Фталазол (Phthalylsulfathiazole)

Official regulatory guidelines strictly define the conditions necessary to store Фталазол tablets to maintain product stability and ensure household safety.

Storage Requirements

Condition	Regulatory Requirement
Temperature	Store at a temperature not exceeding 25 C ( Store below 25 C).
Protection	Keep in a dry place, protected from light.
Packaging	Must be stored in the original container.
Safety	Store out of the sight and reach of children.

Disposal Instructions

Unused or expired Фталазол must be disposed of in accordance with local regulatory requirements. The preferred method is to utilize an authorized drug take-back program. If no such program is available, the product must be mixed with an undesirable substance (such as dirt or used coffee grounds) and placed in a sealed container before being thrown into the household trash. The medicine must not be disposed of by throwing it into wastewater (e.g., flushing).

Фталазол